Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

J.P. Morgan Day 2: Pharma Offers (Some) Views On Drug Pricing Reform

Daily round-up from the virtual J.P. Morgan Healthcare Conference: Novartis explains its PD-1 deal; Biogen partners with Apple; Sanofi and Merck discuss business development priorities; and why AbbVie is confident it can grow without relying on deals. 

Pricing Debate Business Strategies Companies

Latest From Pricing Debate

Medicare Payment Cuts For Vaccines: MedPac Suggests Moving To New WAC-Reimbursement Formula

Proposal, which could be formally endorsed by MedPac this spring, would lower the payment rates for vaccines while simultaneously moving all preventative vaccine coverage to Medicare Part B. Commission signals further cuts to payment rate, through an average sales priced-based methodology that might eventually be recommended.

Vaccines Medicare

Making The Case For A Legislative Deal On Drug Pricing

Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing behind us with a legislative compromise.

Pricing Debate Legislation

Insulin Report Revives Senate Finance Committee Push On Drug Pricing Legislation

Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.

Pricing Debate Legislation

Will COVID-19 Drive The Decline Of International Reference Pricing?

International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.

Europe International

Drug Pricing Reform Without Innovation Backlash? ICER Aims To Find The Path

With new report looking at price increases rather than launch prices, ICER hopes to show it's possible to set limits without negatively impacting development of medicines. Report takes aim at some common drug industry arguments against price reforms and shows some net prices increasing faster than list prices, making it harder for pharma to divert blame to supply chain.

Pricing Debate Innovation

J.P. Morgan Day 2: Pharma Offers (Some) Views On Drug Pricing Reform

Daily round-up from the virtual J.P. Morgan Healthcare Conference: Novartis explains its PD-1 deal; Biogen partners with Apple; Sanofi and Merck discuss business development priorities; and why AbbVie is confident it can grow without relying on deals. 

Pricing Debate Business Strategies

Stockwatch: New Year, New Politics; Same Old Pricing And Generic Challenges

A positive start to the year for healthcare stocks was accompanied, as usual, by drug price increases. This and the other issues that have been carried over from 2020 remain just as challenging.

Pricing Debate Sales & Earnings

J.P. Morgan 2021: The Show Must Go On

The J.P. Morgan Healthcare Conference will be a virtual event but the industry's biggest business meeting will still lay the groundwork for the year ahead.

Business Strategies Leadership

With US Senate Wins In Georgia, Democrats Gain Path For Rx Price Reform, But It May Be Lower Priority

Razor-thin majorities in both chambers of Congress mean Democrats can’t enact a bold agenda, and the pandemic and attendant recession mean that the initial legislative focus won’t be on Rx issues.

Elections Legislation
See All
UsernamePublicRestriction

Register